Latest announcement! New 398 cases of severe cases treated with COVID-19: effective antiviral is the key
AD |
Recently, the Chinese Center for Disease Control and Prevention released the national novel coronavirus infection situation in September. According to the data, from September 1 to September 30, 2023, 31 provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps reported 398 new severe cases and 45 deaths, including 1 death case of respiratory failure caused by COVID-19 infection and 44 death cases of basic diseases combined with COVID-19 infection
Recently, the Chinese Center for Disease Control and Prevention released the national novel coronavirus infection situation in September. According to the data, from September 1 to September 30, 2023, 31 provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps reported 398 new severe cases and 45 deaths, including 1 death case of respiratory failure caused by COVID-19 infection and 44 death cases of basic diseases combined with COVID-19 infection.
Figure 1 Reports of new severe and fatal cases of COVID-19 infection in China (source: CDC)
COVID-19 in China, the proportion of XBB and its sub branches rose to 100%
According to the report, 11629 valid genome sequences of COVID-19 from local cases were reported by 31 provinces (autonomous regions, municipalities directly under the Central Government) and Xinjiang Production and Construction Corps, all of which were Omikjon variants.
Figure 2 Variation trend of novel coronavirus infected local cases in China (source: CDC)
According to the sampling date, the proportion of XBB and its sub branches remained high, with 99.7% in the 35th week of 2023 (August 28th to September 3rd), 99.8% in the 36th to 38th weeks, and 100.0% in the 39th week (September 25th to October 1st).
Prevent COVID-19 and inoculate the vaccine containing the antigen component of XBB mutant
Experts point out that autumn and winter are the high incidence seasons of respiratory infectious diseases every year. This year is the first autumn and winter after the implementation of "Class B and Class B management" for novel coronavirus infection. People who no longer take strict personal protection measures will be more vulnerable to infection after re exposure.
Research has shown that the current epidemic of XBB and its variants have strong immune escape ability, and the antibodies in the Chinese population have poor neutralizing ability against XBB variants, making them prone to breakthrough infections. In addition, key populations such as the elderly, chronic disease patients, and immunocompromised individuals pose greater risks after infection. Therefore, CDC recently issued the Notice on Printing and Distributing the Work Plan of COVID-19 Vaccination for Key Populations in the Near Future.
The Notice pointed out that during the epidemic period of the XBB variant, especially in order to prepare for the COVID-19 this autumn and winter, elderly people aged 60 and above or people aged 18-59 with more serious basic diseases, people with low immune function, people at high risk of infection, and people who have completed basic immunization or have been infected with COVID-19, should be vaccinated with vaccines containing the antigen of the XBB variant.
Accidentally taken, effective antiviral therapy is the key to treatment
Vaccination is an important means to prevent COVID-19 infection, and taking COVID-19 drugs is an effective antiviral treatment.
Traditional Chinese medicine has played an important role in combating the COVID-19. Taking Lianhua Qingwen, one of the "three medicines and three directions" summarized and screened in the national anti epidemic practice, as an example, its formulation combines the essence of the medicine used by famous doctors of the three dynasties to treat epidemic diseases. It uses the Maxing Shigan Decoction, which is specially used to treat epidemic diseases in Treatise on Febrile Diseases by Zhang Zhongjing of the Han Dynasty, and the Yinqiao powder, which is specially used to treat epidemic diseases in Treatise on Febrile Diseases by Wu Jutong of the Qing Dynasty, to learn from the experience of rhubarb in treating epidemic diseases in Treatise on Febrile Diseases by Wu Youke of the Ming Dynasty. The innovative addition of Rhodiola in the formula has the function of improving the human immune system. The synergistic effect of the entire formula has a good therapeutic effect on symptoms of exogenous warm heat diseases such as fever, cough, sore throat, fatigue, and muscle soreness.
Modern pharmacological research has found that Lianhua Qingwen has good antipyretic, cough relieving, anti-inflammatory, and antiviral effects. Xin Liang Xuan Lun and Xie Re can solve patients' fever problems; Clearing the lungs, relieving cough, and asthma can improve patients' persistent cough and pharyngeal pain; The anti-inflammatory and antiviral effects can inhibit virus replication, inhibit systemic inflammatory reactions, and treat both symptoms and symptoms.
Because of its good clinical efficacy in treating COVID-19 infection in the three-year epidemic, Lianhua Qingwen has been included in the diagnosis and treatment plan or guideline consensus for infectious diseases such as COVID-19 infection issued by the National Health Commission and the State Administration of Traditional Chinese Medicine for 34 times, which can be said to be well-known.
With the advent of autumn and winter, although the prevalence of COVID-19 infection is still at a low level, it is not ruled out that the number of infected people will continue to increase, even the possibility of large-scale outbreaks. Experts remind that prevention is the first step, so please do a good job of personal protection. While completing the whole COVID-19 vaccination or strengthening the vaccination in time, prepare treatment drugs to build a healthy defense line. (Written by Sun Haiyan)
Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])
Mobile advertising space rental |
Tag: cases Latest announcement New of severe treated with COVID-19
Nobel laureate visits People's Hospital of Wuhan University
NextMultiple exposures of "fake riders" fabricating scripts and filming videos: Someone being detained or banned
Guess you like
-
WeChat's Official Account Launches "Author Read Aloud Voice" Feature for Personalized Article ListeningDetail
2024-12-18 17:19:57 1
-
The 12th China University Students' Polymer Materials Innovation and Entrepreneurship Competition Finals Grand Opening in Guangrao CountyDetail
2024-12-18 16:04:28 1
-
Tracing the Ancient Shu Road, Winds of the Three Kingdoms: Global Influencer Shu Road Journey LaunchesDetail
2024-12-18 15:23:35 1
-
Seres: A Pioneer in ESG Practices, Driving Sustainable Development of China's New Energy Vehicle IndustryDetail
2024-12-17 16:20:26 1
- Detail
-
My Health, My Guard: Huawei WATCH D2 Aids Precise Blood Pressure Management in the Winter Health BattleDetail
2024-12-17 09:36:15 1
-
Investigation into the Chaos of Airline Seat Selection: Paid Seat Selection, Seat Locking Mechanisms, and Consumer Rights ProtectionDetail
2024-12-15 16:45:48 1
-
Japanese Scientists Grow Human Organs in Pigs: A Balancing Act of Breakthrough and EthicsDetail
2024-12-14 19:48:50 1
-
Pang Donglai and Sam's Club: Two Paths to Transformation in China's Retail IndustryDetail
2024-12-14 17:57:03 1
-
In-Depth Analysis of China's Precision Reducer Industry: Technological Innovation and Market CompetitionDetail
2024-12-14 16:04:26 1
-
Alibaba's "TAO" App Launches in Japan, Targeting High-Quality Service and Convenient LogisticsDetail
2024-12-13 13:22:23 1
-
In-depth Analysis of China's Cross-border E-commerce Industry Chain: Opportunities and Challenges CoexistDetail
2024-12-13 11:37:17 1
-
Sweet Potato Robotics: How a Unified Software and Hardware Computing Platform Accelerates Robotics Industry DevelopmentDetail
2024-12-13 06:36:34 1
- Detail
-
Yang Liwei: From China's First Taikonaut to a Cornerstone of the Space ProgramDetail
2024-12-12 03:27:26 1
- Detail
- Detail
-
12306 Official Debunks 90-Day Advance Booking for Spring Festival Travel Rush: Beware of ScamsDetail
2024-12-12 02:01:05 1
-
Avoiding TV Buying Traps: A Deep Dive into 4K, HDR, 120Hz, and Other Key SpecificationsDetail
2024-12-11 22:45:54 1
-
NVIDIA's Q3 FY25 Earnings Report: Revenue Surges Past $35 Billion, Setting a New RecordDetail
2024-12-11 21:48:21 1